Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: Data from the Korean College of Rheumatology BIOlogics (KOBIO) registry

<p><b>Objective:</b> We investigated whether body mass index (BMI) is associated with parameters of disease activity and clinical manifestations in axial spondyloarthritis (axSpA).</p> <p><b>Methods:</b> Demographic, clinical, and radiological features and disease activity indexes from 789 axSpA patients (619 males and 170 females) were obtained from the Korean College of Rheumatology BIOlogics (KOBIO) registry. BMI (kg/m²) was classified into normal (BMI <23.0), overweight (23.0 ≤ BMI <25.0), and obese (BMI ≥25.0). Disease activity indexes included Bath ankylosing spondylitis disease activity index (BASDAI), erythrocyte sediment rate (ESR), C-reactive protein (CRP), and ankylosing spondylitis disease activity score (ASDAS).</p> <p><b>Results:</b> The mean BMI in patients with axSpA was 23.3 ± 3.5. 50.2% of all patients were overweight or obese. Overweight/obese patients had more syndesmophyte and less peripheral arthritis than those in normal BMI patients (<i>p</i> < 0.001 and <i>p</i> < 0.030, respectively). BMI was not associated with disease activity indexes in axSpA patients. Patients with syndesmophyte had higher BMI than those without syndesmophyte (24.2 ± 3.6 vs. 22.9 ± 3.3, <i>p</i> < 0.001). Multivariate logistic regression analysis showed that increased BMI was closely related with the presence of syndesmophyte (OR = 1.086, 95% CI 1.031–1.143, <i>p</i> = 0.002)</p> <p><b>Conclusions:</b> Our results imply that increased BMI is significantly associated with the presence of syndesmophyte, but not with disease activity in axSpA.</p

Table_1_Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis.docx

Unlike other biologic agents for rheumatoid arthritis (RA) that are administered at regular intervals even without flare, rituximab can be administered according to the timing of retreatment determined by the physician. Recently, there has been a tendency to prefer on-demand administration for disease flares rather than regular retreatment. We aimed to investigate the retreatment patterns of rituximab in patients with RA and to identify factors associated with extension of the time interval between retreatment courses. This study included RA patients on rituximab treatment who were enrolled in the Korean Rheumatology Biologics registry (KOBIO) or treated at Ajou University Hospital. Previous or current concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), corticosteroids, number of previous biologic agents, withdrawal, and time intervals of rituximab retreatment were collected. In case of treatment failure, the reasons such as lack of efficacy, adverse events, and others, were also identified. A total of 82 patients were enrolled. The mean follow-up period from the first cycle of rituximab was 46.1 months, and the mean interval between the retreatment courses was 16.3 months. The persistent rates of rituximab after 5 years was 72.4%. Concomitant use of at least two csDMARDs (β = 4.672; 95% CI: 0.089–9.255, p = 0.046) and concomitant use of corticosteroids (β = 7.602; 95% CI: 0.924–14.28, p = 0.026) were independent factors for extending the time interval between the retreatment courses. In conclusion, RA patients treated with rituximab in Korea show high persistence rates. Concomitant use of two or more csDMARDs and concomitant use of corticosteroids with rituximab are associating factors of extending the retreatment time interval. These findings should be considered when selecting rituximab as a treatment for patients with RA.</p

sj-docx-1-tab-10.1177_1759720X221091450 – Supplemental material for Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure

Supplemental material, sj-docx-1-tab-10.1177_1759720X221091450 for Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure by Dong-Jin Park, Sung-Eun Choi, Ji-Hyoun Kang, Kichul Shin, Yoon-Kyoung Sung and Shin-Seok Lee in Therapeutic Advances in Musculoskeletal Disease</p

sj-docx-1-tab-10.1177_1759720X231201714 – Supplemental material for The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry

Supplemental material, sj-docx-1-tab-10.1177_1759720X231201714 for The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry by Jinhyun Kim, Min Jung Kim, Geun Young Oh, Sun Kyung Lee, Taeeun Kim and Kichul Shin in Therapeutic Advances in Musculoskeletal Disease</p

Additional file 1: of Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study

Figure S1. Flow chart of inclusion. Figure S2. Dynamic changes in dose quotient (DQ) of TNFi in included patients during the follow-up (time level). Figure S3. Proportion of 1-year intervals achieving (A) ASDAS-low disease activity, (B) ASAS20, (C) ASAS40, (D) BASDAI < 4, and (E) CRP < 0.5 mg/dL. Table S1. Effect of tapering TNFi on the achievement of various outcomes in 1-year intervals. Table S2. Effect of tapering DQ on maintaining ASDAS-ID in subsequent 1-year intervals in the subgroup of patients who showed ASDAS-low disease activity (1.3 ≤ ASDAS-CRP < 2.1) at 1-year follow-up (n = 254). Table S3. Multivariable longitudinal model where all clinically relevant factors were included as covariates. Table S4. Effect of tapered DQ on the achievement of consecutive ASDAS-ID in the subgroup of patients who completed 3-year follow-up. (DOCX 1150 kb

Additional file 1 of Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry

Additional file 1: Supplement Table 1. Comparison of disease activity markers between D2T and non-D2T group. Supplementary Table 2. Comparison of adverse events causing drug withdrawal in D2T and non-D2T group. Supplementary Table 3. Logistic regression analysis for adverse events in patients with D2T RA

Data_Sheet_1_The Aftermath of Tapering Tocilizumab After Achieving Treatment Target in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study.docx

BackgroundAlthough recent guidelines recommend that tapering of biologic disease-modifying anti-rheumatic drugs (bDMARDs) can be considered in patients with rheumatoid arthritis (RA), there has been little evidence supporting the strategy during the non-tumor necrosis factor inhibitor treatment. This study aims to investigate the effectiveness and safety of tapering tocilizumab (TCZ) dose in patients with RA who attain low disease activity (LDA) after TCZ therapy in a nationwide cohort.MethodsData were collected from a nationwide cohort of patients with RA receiving biologic disease-modifying anti-rheumatic drugs in South Korea (KOBIO-RA). This study included 350 patients who were treated with TCZ and achieved Clinical Disease Activity Index-low disease activity (CDAI)-LDA (CDAI ≤ 10) after 1 year of treatment. We performed longitudinal analysis considering clinical data measured at all 1-year intervals for the included patients using the generalized estimating equation. A total of 575 intervals were classified into two groups according to their dose quotient (DQ) of TCZ (tapering group vs. standard-dose group). The main outcome was maintaining CDAI-LDA in the following 1-year interval.ResultsTapering TCZ dose strategy was used in 282 (49.0%) intervals with a mean (SD) DQ of 66.0 (15.5) %. Loss of CDAI-LDA occurred in 91 (15.1%) intervals. Multivariable GEE showed that the tapering group was associated with more frequent failure to sustain CDAI-LDA (adjusted OR [95% CI]: 0.57 [0.33–0.99]), which subsequently led to impaired functional status. The likelihood of achieving DAS28-deep remission (DAS28-ESR ConclusionsTapering TCZ dose after achieving LDA increases the risk of losing LDA without a significant merit in safety.</p

Effect of androgen-deprivation therapy (ADT) on the longitudinal serum uric acid (SUA) change in the whole population and post-matched population.

Effect of androgen-deprivation therapy (ADT) on the longitudinal serum uric acid (SUA) change in the whole population and post-matched population.</p

Longitudinal changes in serum urate (SUA) levels according to the subgroups.

Hyperuricemia (SUA ≥7.0 mg/dL), normouricemia (4.0≤ and <7.0 mg/dL), and hypouricemia (<4.0 mg/dL) were defined by using the baseline SUA levels. P values were corrected by the Bonferroni method. * p <0.05 between the baseline and 6-month time points; †, p <0.05 when compared between the surgery and ADT groups at each time point.</p

Effect of the interaction between a specific clinical factor and time on the longitudinal serum uric acid (SUA) levels.

Effect of the interaction between a specific clinical factor and time on the longitudinal serum uric acid (SUA) levels.</p